Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX)

Charles Schwab Investment Management Inc. acquired a new stake in MBX Biosciences, Inc. (NYSE:MBX) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 93,311 shares of the company’s stock, valued at approximately $1,720,000.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers bought a new stake in MBX Biosciences during the fourth quarter worth approximately $175,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of MBX Biosciences during the 3rd quarter worth $278,000. Point72 Asset Management L.P. acquired a new position in MBX Biosciences in the 3rd quarter valued at $405,000. Barclays PLC bought a new position in MBX Biosciences in the 3rd quarter worth $426,000. Finally, Geode Capital Management LLC bought a new position in MBX Biosciences in the 3rd quarter worth $579,000.

Insider Buying and Selling

In related news, CEO P. Kent Hawryluk purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were bought at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the transaction, the chief executive officer now directly owns 448,277 shares of the company’s stock, valued at approximately $4,792,081.13. This trade represents a 12.55 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carl L. Gordon acquired 47,502 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $9.87 per share, for a total transaction of $468,844.74. Following the acquisition, the director now owns 3,205,930 shares in the company, valued at approximately $31,642,529.10. This trade represents a 1.50 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 240,672 shares of company stock valued at $2,555,308.

MBX Biosciences Price Performance

MBX stock opened at $7.76 on Friday. The company’s 50-day moving average price is $9.89. MBX Biosciences, Inc. has a 52-week low of $7.25 and a 52-week high of $27.50.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.